HOOK Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | Reilly Timothy P. | director | 40,000 | A-Award | A | 40,000 | 1.63 | 65,200.00 |
| 2022-06-30 | van de Winkel Jan | director | 40,000 | A-Award | A | 40,000 | 1.63 | 65,200.00 |
| 2022-06-30 | Orlinger Klaus | officer: Chief Scientific Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-06-30 | Necina Roman | officer: Chief Technology Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-06-30 | O'Neill Julie | director | 20,000 | A-Award | A | 20,000 | 1.63 | 32,600.00 |
| 2022-06-30 | Matushansky Igor | officer: Chief Medical Officer | 92,950 | A-Award | A | 92,950 | 1.66 | 154,297.00 |
| 2022-06-30 | Kelly Michael Aaron | director | 20,000 | A-Award | A | 20,000 | 1.63 | 32,600.00 |
| 2022-06-30 | Kaufman David Ross | director | 20,000 | A-Award | A | 20,000 | 1.63 | 32,600.00 |
| 2022-06-30 | Aldag Jorn | director, officer: Chief Executive Officer | 275,250 | A-Award | A | 275,250 | 1.66 | 456,915.00 |
| 2022-06-30 | Baker Christine D. | officer: Chief Operating Officer | 100,000 | A-Award | A | 100,000 | 1.66 | 166,000.00 |
| 2022-06-30 | Kandera Reinhard | director, officer: Chief Financial Officer | 92,950 | A-Award | A | 92,950 | 1.66 | 154,297.00 |
| 2022-04-19 | Necina Roman | officer: Chief Technology Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-04-19 | Orlinger Klaus | officer: Chief Scientific Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-04-19 | Matushansky Igor | officer: Chief Medical Officer | 92,950 | A-Award | A | 92,950 | 1.66 | 154,297.00 |
| 2022-04-19 | Baker Christine D. | officer: Chief Business Officer | 100,000 | A-Award | A | 100,000 | 1.66 | 166,000.00 |
| 2022-04-19 | Kandera Reinhard | director, officer: Chief Financial Officer | 92,950 | A-Award | A | 92,950 | 1.66 | 154,297.00 |
| 2022-04-19 | Aldag Jorn | director, officer: Chief Executive Officer | 275,250 | A-Award | A | 275,250 | 1.66 | 456,915.00 |
| 2022-02-01 | Orlinger Klaus | officer: Executive VP, Research | 12,654 | A-Award | A | 12,654 | 1.50 | 18,981.00 |
| 2022-02-01 | Orlinger Klaus | officer: Executive VP, Research | 10,404 | A-Award | A | 9,188 | 3.00 | 27,564.00 |
| 2022-02-01 | Baker Christine D. | officer: Chief Business Officer | 22,763 | A-Award | A | 22,763 | 1.50 | 34,144.50 |
| 2022-02-01 | Baker Christine D. | officer: Chief Business Officer | 16,158 | A-Award | A | 13,658 | 3.00 | 40,974.00 |
| 2022-02-01 | Kandera Reinhard | director, officer: Chief Financial Officer | 23,427 | A-Award | A | 23,427 | 1.50 | 35,140.50 |
| 2022-02-01 | Kandera Reinhard | director, officer: Chief Financial Officer | 16,092 | A-Award | A | 14,056 | 3.00 | 42,168.00 |
| 2022-02-01 | Matushansky Igor | officer: Chief Medical Officer | 24,888 | A-Award | A | 24,888 | 1.50 | 37,332.00 |
| 2022-02-01 | Matushansky Igor | officer: Chief Medical Officer | 100,240 | A-Award | A | 14,933 | 3.00 | 44,799.00 |
| 2022-02-01 | Necina Roman | officer: Chief Technology Officer | 21,486 | A-Award | A | 21,486 | 1.50 | 32,229.00 |
| 2022-02-01 | Necina Roman | officer: Chief Technology Officer | 14,876 | A-Award | A | 12,892 | 3.00 | 38,676.00 |
| 2022-02-01 | Aldag Jorn | director, officer: Chief Executive Officer | 39,853 | A-Award | A | 39,853 | 1.50 | 59,779.50 |
| 2022-02-01 | Aldag Jorn | director, officer: Chief Executive Officer | 51,952 | A-Award | A | 47,824 | 3.00 | 143,472.00 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 4,261 | M-Exempt | D | 3,408 | 0.10 | 340.80 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 2,842 | M-Exempt | D | 11,366 | 0.10 | 1,136.60 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 0 | M-Exempt | D | 8,079 | 0.10 | 807.90 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 85,307 | S-Sale | D | 2,205 | 2.49 | 5,490.45 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 87,512 | M-Exempt | A | 3,408 | 0.10 | 340.80 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 84,104 | S-Sale | D | 7,440 | 2.49 | 18,525.60 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 91,544 | M-Exempt | A | 11,366 | 0.10 | 1,136.60 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 80,178 | S-Sale | D | 5,304 | 2.49 | 13,206.96 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 85,482 | M-Exempt | A | 8,079 | 0.10 | 807.90 |
| 2021-06-01 | van de Winkel Jan | director | 19,200 | A-Award | A | 19,200 | 0.00 | 0.00 |
| 2021-06-01 | Soria Jean-Charles | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | Kaufman David Ross | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | Seghezzi Graziano | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | O'Neill Julie | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | Lengauer Christoph | director | 9,600 | A-Award | A | 9,600 | 0.00 | 0.00 |
| 2021-06-01 | Kelly Michael Aaron | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-04-21 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,177,574 | S-Sale | D | 328,620 | 11.60 | 3,812,386.34 |
| 2021-04-19 | Kandera Reinhard | director, officer: Chief Financial Officer | 69,300 | A-Award | A | 69,300 | 12.00 | 831,600.00 |
| 2021-04-19 | Aldag Jorn | director, officer: Chief Executive Officer | 207,600 | A-Award | A | 207,600 | 12.00 | 2,491,200.00 |
| 2021-04-19 | Baker Christine D. | officer: Chief Business Officer | 49,950 | A-Award | A | 49,950 | 12.00 | 599,400.00 |
| 2021-04-19 | Matushansky Igor | officer: Chief Medical Officer | 95,250 | A-Award | A | 95,250 | 12.00 | 1,143,000.00 |
| 2021-04-19 | Necina Roman | officer: Chief Technology Officer | 36,750 | A-Award | A | 36,750 | 12.00 | 441,000.00 |
| 2021-04-19 | Orlinger Klaus | officer: EVP, Research | 26,050 | A-Award | A | 26,050 | 12.00 | 312,600.00 |
| 2021-03-29 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,506,194 | S-Sale | D | 36,829 | 13.67 | 503,570.28 |
| 2021-03-26 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,543,023 | S-Sale | D | 35,171 | 0.00 | 0.00 |
| 2021-03-25 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,578,194 | S-Sale | D | 28,546 | 13.12 | 374,569.19 |
| 2021-03-24 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,606,740 | S-Sale | D | 52,690 | 13.70 | 721,615.89 |
| 2021-03-23 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,659,430 | S-Sale | D | 40,000 | 13.91 | 556,476.00 |
| 2021-03-22 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,699,430 | S-Sale | D | 40,534 | 14.54 | 589,263.03 |
| 2021-03-19 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,739,964 | S-Sale | D | 166,230 | 0.00 | 0.00 |
| 2020-12-17 | Matushansky Igor | officer: Chief Medical Officer | 64,253 | S-Sale | D | 11,501 | 11.70 | 134,561.70 |
| 2020-12-17 | Matushansky Igor | officer: Chief Medical Officer | 8,079 | M-Exempt | D | 31,656 | 0.00 | 0.00 |
| 2020-12-17 | Matushansky Igor | officer: Chief Medical Officer | 14,208 | M-Exempt | D | 11,367 | 0.00 | 0.00 |
| 2020-12-17 | Matushansky Igor | officer: Chief Medical Officer | 7,669 | M-Exempt | D | 5,965 | 0.00 | 0.00 |
| 2020-12-17 | Matushansky Igor | officer: Chief Medical Officer | 75,754 | M-Exempt | A | 19,360 | 0.10 | 1,936.00 |
| 2020-12-17 | Matushansky Igor | officer: Chief Medical Officer | 77,403 | S-Sale | D | 16,478 | 11.76 | 193,781.28 |
| 2020-12-17 | Matushansky Igor | officer: Chief Medical Officer | 93,881 | M-Exempt | A | 29,628 | 0.10 | 2,962.80 |
| 2020-12-16 | Matushansky Igor | officer: Chief Medical Officer | 56,394 | S-Sale | D | 380 | 11.70 | 4,446.00 |
| 2020-12-16 | Matushansky Igor | officer: Chief Medical Officer | 56,774 | M-Exempt | A | 640 | 0.10 | 64.00 |
| 2020-12-16 | Matushansky Igor | officer: Chief Medical Officer | 39,735 | M-Exempt | D | 640 | 0.10 | 64.00 |
| 2020-12-15 | Soria Jean-Charles | director | 19,200 | A-Award | A | 19,200 | 0.00 | 0.00 |
| 2020-10-21 | Kaufman David Ross | director | 4,577 | A-Award | A | 4,577 | 0.00 | 0.00 |
| 2020-10-21 | van Deventer Sander | director | 2,485 | A-Award | A | 2,485 | 0.00 | 0.00 |
| 2020-10-21 | Seghezzi Graziano | director | 4,708 | A-Award | A | 4,708 | 0.00 | 0.00 |
| 2020-10-21 | van de Winkel Jan | director | 9,153 | A-Award | A | 9,153 | 0.00 | 0.00 |
| 2020-10-21 | Kelly Michael Aaron | director | 5,754 | A-Award | A | 5,754 | 0.00 | 0.00 |
| 2020-10-21 | Lengauer Christoph | director | 4,603 | A-Award | A | 4,603 | 0.00 | 0.00 |
| 2020-10-21 | O'Neill Julie | director | 4,969 | A-Award | A | 4,969 | 0.00 | 0.00 |
| 2020-10-02 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,906,194 | S-Sale | D | 300 | 10.00 | 3,000.00 |
| 2020-09-15 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,906,494 | S-Sale | D | 9,261 | 13.16 | 121,912.73 |
| 2020-09-15 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,915,755 | S-Sale | D | 32,336 | 12.45 | 402,563.80 |
| 2020-07-20 | Kandera Reinhard | director, officer: Chief Financial Officer | 2,036 | A-Award | A | 2,036 | 0.00 | 0.00 |
| 2020-07-20 | Aldag Jorn | director, officer: Chief Executive Officer | 4,128 | A-Award | A | 4,128 | 0.00 | 0.00 |
| 2020-07-20 | Matushansky Igor | officer: Chief Medical Officer | 56,134 | A-Award | A | 2,736 | 0.00 | 0.00 |
| 2020-07-20 | Necina Roman | officer: Chief Technology Officer | 1,984 | A-Award | A | 1,984 | 0.00 | 0.00 |
| 2020-07-20 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,948,091 | S-Sale | D | 12,483 | 11.94 | 149,101.95 |
| 2020-07-20 | Orlinger Klaus | officer: EVP, Research | 1,216 | A-Award | A | 1,216 | 0.00 | 0.00 |
| 2020-06-29 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,960,574 | S-Sale | D | 3,280 | 11.78 | 38,627.58 |
| 2020-06-18 | Seghezzi Graziano | director | 9,600 | A-Award | A | 9,600 | 11.45 | 109,920.00 |
| 2020-06-18 | O'Neill Julie | director | 9,600 | A-Award | A | 9,600 | 11.45 | 109,920.00 |
| 2020-06-18 | Lengauer Christoph | director | 9,600 | A-Award | A | 9,600 | 11.45 | 109,920.00 |
| 2020-06-18 | van de Winkel Jan | director | 19,200 | A-Award | A | 19,200 | 11.45 | 219,840.00 |
| 2020-06-18 | Kelly Michael Aaron | director | 9,600 | A-Award | A | 9,600 | 0.00 | 0.00 |
| 2020-06-18 | Kaufman David Ross | director | 9,600 | A-Award | A | 9,600 | 11.45 | 109,920.00 |
| 2020-06-18 | van Deventer Sander | director | 9,600 | A-Award | A | 9,600 | 0.00 | 0.00 |
| 2020-04-20 | Necina Roman | officer: Chief Technology Officer | 0 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2020-04-20 | Kandera Reinhard | director, officer: Chief Financial Officer | 0 | A-Award | A | 77,400 | 8.03 | 621,522.00 |
| 2020-04-20 | Matushansky Igor | officer: Chief Medical Officer | 0 | A-Award | A | 65,200 | 8.03 | 523,556.00 |
| 2020-04-20 | Orlinger Klaus | officer: EVP, Research | 0 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2020-04-20 | Aldag Jorn | director, officer: Chief Executive Officer | 0 | A-Award | A | 200,000 | 8.03 | 1,606,000.00 |
| 2020-01-29 | Matushansky Igor | officer: Chief Medical Officer | 53,398 | S-Sale | D | 5,500 | 12.73 | 69,992.45 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.